Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203787 | 0.86 | TDP1 (0.70) | KMT2AMEN1TSHRRECQLRAB9A | |
| SCHEMBL15868883 | 0.85 | KMT2A (0.67) | KMT2AMEN1TSHRRECQLRAB9A | |
| SCHEMBL2538911 | 0.82 | TDP1 (0.74) | KMT2AMEN1TSHRRECQLRAB9A | |
| SCHEMBL19311844 | 0.82 | TSHR (0.68) | KMT2AMEN1TSHRRECQLRAB9A | |
| SCHEMBL4303747 | 0.80 | ALDH1A1 (0.65) | KMT2AMEN1TSHRRECQLRAB9A | |
| SCHEMBL20063716 | 0.79 | KMT2A (0.59) | KMT2AMEN1TSHRRECQLRAB9A | |
| SCHEMBL15758442 | 0.78 | KMT2A (0.58) | KMT2AMEN1TSHRRECQLRAB9A | |
| SCHEMBL16585160 | 0.77 | TSHR (0.61) | KMT2AMEN1TSHRRECQLRAB9A | |
| SCHEMBL10746769 | 0.77 | KDM4E (0.60) | KMT2AMEN1TSHRRECQLRAB9A | |
| SCHEMBL29457684 | 0.77 | KDM4E (0.60) | KMT2AMEN1TSHRRECQLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023226241-A1 | PHENYLACETAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 湖南省农业生物技术研究所 | 2023-11-30 | — | — | WO | disclosed |
| WO-2023226241-A1 | PHENYLACETAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 湖南省农业生物技术研究所 | 2023-11-30 | — | — | WO | disclosed |
| CN-114957166-B | Phenylacetamide compound and preparation method and application thereof | 湖南省农业生物技术研究所 | 2023-07-25 | — | — | CN | disclosed |
| US-20230165815-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER?S DISEASE | Lu, Qun (US) | 2023-06-01 | — | — | US | disclosed |
| CN-114957166-A | Phenylacetamide compound and preparation method and application thereof | 湖南省农业生物技术研究所 | 2022-08-30 | — | — | CN | disclosed |
| US-20170334863-A1 | Cdc42 INHIBITOR AND USES THEREOF | LU QUN (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334863-A1 | Cdc42 INHIBITOR AND USES THEREOF | LU QUN (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334863-A1 | Cdc42 INHIBITOR AND USES THEREOF | LU QUN (CN) | 2017-11-23 | — | — | US | disclosed |
| EP-2716292-B1 | CDC42 INHIBITOR AND USES THEREOF | ONCO BIOMEDICAL TECH (SUZHOU) CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| EP-2716292-B1 | CDC42 INHIBITOR AND USES THEREOF | ONCO BIOMEDICAL TECH (SUZHOU) CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| US-9725417-B2 | Cdc42 inhibitor and uses thereof | LU QUN (CN) | 2017-08-08 | — | — | US | disclosed |
| US-9725417-B2 | Cdc42 inhibitor and uses thereof | LU QUN (CN) | 2017-08-08 | — | — | US | disclosed |
| US-9725417-B2 | Cdc42 inhibitor and uses thereof | LU QUN (CN) | 2017-08-08 | — | — | US | disclosed |
| US-20150329496-A1 | Cdc42 INHIBITOR AND USES THEREOF | LU QUN (CN) | 2015-11-19 | — | — | US | disclosed |
| US-20150329496-A1 | Cdc42 INHIBITOR AND USES THEREOF | LU QUN (CN) | 2015-11-19 | — | — | US | disclosed |
| US-20150329496-A1 | Cdc42 INHIBITOR AND USES THEREOF | LU QUN (CN) | 2015-11-19 | — | — | US | disclosed |
| US-20140194451-A1 | Cdc42 Inhibitor and Uses Thereof | LU QUN (CN) | 2014-07-10 | — | — | US | disclosed |
| US-20140194451-A1 | Cdc42 Inhibitor and Uses Thereof | LU QUN (CN) | 2014-07-10 | — | — | US | disclosed |
| CN-102796050-A | Cdc42 inhibitor and application thereof | ANGKE BIOLOG MEDICLA TECHNOLOGY SUZHOU CO LTD | 2012-11-28 | — | — | CN | disclosed |
| US-5139564-A | Applying postemergence | PARK SANG W (KR) | 1992-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165815-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER?S DISEASE | CDC42, MDN1, GAP43 | KMT2A 4297/4885MEN1 3675/4885TSHR 3939/4885 |
| US-20150329496-A1 | Cdc42 INHIBITOR AND USES THEREOF | CDC42, ARHGDIA, ARHGDIB | KMT2A 4714/4885MEN1 2962/4885TSHR 4308/4885 |
| US-20170334863-A1 | Cdc42 INHIBITOR AND USES THEREOF | CDC42, ARHGDIA, ARHGDIB | KMT2A 4735/4885MEN1 2931/4885TSHR 4362/4885 |
| US-20140194451-A1 | Cdc42 Inhibitor and Uses Thereof | CDC42, ARHGDIA, ARHGDIB | KMT2A 4715/4885MEN1 2991/4885TSHR 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.